Publications by authors named "Mark R Player"

Claim this Profile
P
Pan AMPK activation protects tubules in rat ischemic acute kidney injury.
Henriette Frikke-Schmidt, Kamal Albarazanji, Jenson Qi, David Frederick, Janos Steffen, Mark R Player

J Pharmacol Exp Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a GPR40 Superagonist: The Impact of Aryl Propionic Acid α-Fluorination.
Hui Huang, Sanath K Meegalla, James C Lanter, Michael P Winters, Shuyuan Zhao, Mark R Player

ACS Med Chem Lett· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury.
Monicah A Otieno, Jan Snoeys, Wing Lam, Avi Ghosh, Mark R Player

Toxicol Sci· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GPR40-Mediated G12 Activation by Allosteric Full Agonists Highly Efficacious at Potentiating Glucose-Stimulated Insulin Secretion in Human Islets.
Marie-Laure Rives, Brian Rady, Nadia Swanson, Shuyuan Zhao, Jenson Qi, Mark R Player

Mol Pharmacol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR40 agonists.
Hui Huang, Michael P Winters, Sanath K Meegalla, Eric Arnoult, S Paul Lee, Mark R Player

Bioorg Med Chem Lett· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a novel potent GPR40 full agonist.
Sanath K Meegalla, Hui Huang, Tonya Martin, June Xu, Shuyuan Zhao, Mark R Player

Bioorg Med Chem Lett· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agents.
Raymond J Patch, Hui Huang, Sharmila Patel, Wing Cheung, Guozhang Xu, Mark R Player

Eur J Med Chem· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors.
Sanath K Meegalla, Hui Huang, Carl R Illig, Daniel J Parks, Jinsheng Chen, Mark R Player

Bioorg Med Chem Lett· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep).
William H Parsons, Raul R Calvo, Wing Cheung, Yu-Kai Lee, Sharmila Patel, Mark R Player

J Med Chem· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transient receptor potential melastatin 8 channel inhibition potentiates the hypothermic response to transient receptor potential vanilloid 1 activation in the conscious mouse.
Viktor V Feketa, Yi Zhang, Zhijuan Cao, Adithya Balasubramanian, Christopher M Flores, Mark R Player

Crit Care Med· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors.
Carl R Illig, Carl L Manthey, Sanath K Meegalla, Mark J Wall, Jinsheng Chen, Mark R Player

Bioorg Med Chem Lett· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shivering and tachycardic responses to external cooling in mice are substantially suppressed by TRPV1 activation but not by TRPM8 inhibition.
Viktor V Feketa, Adithya Balasubramanian, Christopher M Flores, Mark R Player, Sean P Marrelli

Am J Physiol Regul Integr Comp Physiol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of vinylcycloalkyl-substituted benzimidazole TRPM8 antagonists effective in the treatment of cold allodynia.
Raul R Calvo, Sanath K Meegalla, Daniel J Parks, William H Parsons, Shelley K Ballentine, Mark R Player

Bioorg Med Chem Lett· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).
Carl R Illig, Carl L Manthey, Mark J Wall, Sanath K Meegalla, Jinsheng Chen, Mark R Player

J Med Chem· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developments in factor Xa inhibitors for the treatment of thromboembolic disorders.
Yu-Kai Lee, Mark R Player

Med Res Rev· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents.
Raymond J Patch, Lily L Searle, Alexander J Kim, Debyendu De, Xizhen Zhu, Mark R Player

J Med Chem· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.
Daniel J Parks, William H Parsons, Raymond W Colburn, Sanath K Meegalla, Shelley K Ballentine, Mark R Player

J Med Chem· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bradykinin B1 receptor antagonists as potential therapeutic agents for pain.
Hui Huang, Mark R Player

J Med Chem· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.
Kenneth J Wilson, Carl R Illig, Jinsheng Chen, Mark J Wall, Shelley K Ballentine, Mark R Player

Bioorg Med Chem Lett· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.
Tianbao Lu, Thomas Markotan, Shelley K Ballentine, Edward C Giardino, John Spurlino, Mark R Player

J Med Chem· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein kinase inhibitors for the treatment of inflammatory disease.
Mark R Player

Curr Top Med Chem· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease.
Sharmila Patel, Mark R Player

Curr Top Med Chem· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein kinase inhibitors for the treatment of inflammatory disease.
Mark R Player

Curr Top Med Chem· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrido[2,3-d]pyrimidin-5-ones: a novel class of antiinflammatory macrophage colony-stimulating factor-1 receptor inhibitors.
Hui Huang, Daniel A Hutta, James M Rinker, Huaping Hu, William H Parsons, Mark R Player

J Med Chem· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
Sharmila Patel, Mark R Player

Expert Opin Investig Drugs· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis